Latest Breaking News On - Dyax corp - Page 4 : comparemela.com

Mark Enyedy is currently chief executive of Nasdaq-listed ImmunoGen There will be a new face around the Ergomed boardroom table Growing pharma services group Ergomed PLC (LON:ERGO) has appointed Mark Enyedy as its new independent director. Currently chief executive of Nasdaq-listed ImmunoGen, he was formerly head of corporate development for Shire where he oversaw the acquisitions of NPS Pharmaceuticals and Dyax Corp along with its US$32bn combination with Baxalta. Ergomed chairman, Dr Miroslav Reljanović, said: Mark has extensive corporate development experience in the US, UK and globally from his time in senior public company strategic leadership roles. “Throughout his career he has achieved an outstanding and consistent track record of building new businesses through organic growth, corporate development, and M&A.

United kingdomMark enyedyMiroslav reljanoviDyax corpஒன்றுபட்டது கிஂக்டம்